Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
ADMA STOCK DROP ALERT: ADMA Biologics, Inc. Stock Drops over 20%; BFA Law Initiates Securities Fraud Investigation and Urges Investors with Losses to Contact the Firm (Nasdaq:ADMA)
NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts
The latest trading day saw Adma Biologics (ADMA) settling at $20.33, representing a -1.91% change from its previous close.
The Real Best Stock Of The Year Isn't In The S&P 500 Yet
If you're like most investors — you assume AI giant Nvidia is the best stock of the year. But 2024's major champ isn't even in the S&P 500.
New Strong Buy Stocks for October 7th
ADMA, VERX, TRGP, EBMT and TALO have been added to the Zacks Rank #1 (Strong Buy) List on October 7, 2024.
Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Adma Biologics (ADMA) closed at $19.50, indicating a -1.37% shift from the previous trading day.
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Here is how Adma Biologics (ADMA) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.
ADMA Biologics: Riding High On ASCENIV's Success
ADMA Biologics reported $107.2 million in Q2 2024 revenue, a 78% year-over-year increase, with ASCENIV being the primary growth driver. ASCENIV now contributes over 50% of ADMA's total revenue, with significant market potential in treating refractory immunodeficient patients. ASCENIV's unique formulation and potential market penetration could drive peak annual sales over $1 billion, though technological advancements and existing competition pose risks.
Adma Biologics (ADMA) Is a Great Choice for 'Trend' Investors, Here's Why
Adma Biologics (ADMA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Biotech Hangs On To Top Spot On This List, And It Even Outshines Nvidia
This biopharma stock has gained around 330% so far this year and is near record highs.
Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $19.44, denoting a -0.26% change from the preceding trading day.
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest?
ADMA stock surges 76.2% in three months on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.
Here's Why Momentum in Adma Biologics (ADMA) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
